Product Description
Tirzepatide acts on both GLP-1 and GIP receptors. It boosts insulin release, suppresses glucagon, slows gastric emptying and strongly curbs appetite. It delivers stronger hypoglycemic and fat-burning effects than single GLP-1 drugs, improves insulin resistance and overall metabolism efficiently.
Indications
- Glycemic control in adults with type 2 diabetes mellitus
- Long-term weight management for overweight and obese population
- Improve blood lipid levels and reduce cardiovascular risks
- Auxiliary metabolic conditioning combined with diet and exercise
Administration
- Only for subcutaneous injection: abdomen, thigh or upper arm
- Not for IV or IM use
- Fixed time once weekly injection
- Start with low dose, titrate gradually as medical advice
Product Features
- Dual-target mechanism, stronger efficacy
- Excellent blood sugar stabilization effect
- Outstanding rapid weight loss performance
- Low hypoglycemia incidence
- Once-weekly dosing, high compliance
- Prefilled pen, easy self-administration
Storage
- Unopened: Store at 2°C ~ 8°C refrigeration, avoid freezing and direct sunlight
- After use: Keep refrigerated, finish within valid period
Warnings
- Prescription-only medicine, use strictly under doctor supervision
- Contraindicated in history of medullary thyroid carcinoma
- Avoid use in patients with hypersensitivity to tirzepatide or ingredients
- Common mild reactions: nausea, vomiting, constipation, usually fade over time
- Not for type 1 diabetes and diabetic ketoacidosis
- Not recommended for pregnant, lactating women and minors
- Keep out of reach of children
